Table 1.
List of meta-analyses on the risk of VTEs during treatment with JAKis
| First author |
Date of publication | JAK inhibitor | Indication | Studies included (n) | Type of studies included | Patients included (n) | Median follow-up (weeks) | Events among exposed participants (n) | Events among non-exposed participants (n) | Results OR (95% CI) |
Methods used |
| Xie et al31 | 2019 | Tofacitinib, baricitinib, upadacitinib, peficitinib, decernotinib | RA | 26 | RCT | 11 799 | Placebo-controlled period: 12 Dose-comparison period: 24 |
12 | 3 | All JAKis: 1.16 (0.48 to 2.81) Tofacitinib: 0.17 (0.03 to 1.05) Baricitinib: 2.33 (0.62 to 8.75) Upadacitinib: 1.77 (0.20 to 16.00) |
Mantel-Haenszel fixed-effect method |
| Xie et al32 | 2019 | Tofacitinib | RA, PsA, CPP, UC, CD, AS | 27 | RCT | 13 611 | Placebo-controlled period: 12 Dose-comparison period: 24 |
1 | 5 | 0.03 (0.00 to 0.21) | Peto method |
| Olivera et al33 | 2020 | Tofacitinib, upadacitinib, filgotinib, baricitinib | RA, AS, UC, CD, CPP | 10 | RCT Cohorts |
5143 | 26 | 12 | 3 | All JAKis: 0.90 (0.32 to 2.54) | Random-effect model |
| Giménez Poderós et al34 | 2020 | Tofacitinib, baricitinib | RA, KT, UC, CPP, CD, PsA, AD, DKD, SLE, JIA, SS | 59 | RCT Cohorts |
25 947 | 16 | 24 | 23 | Tofacitinib: 0.29 (0.10 to 0.84) Baricitinib: 3.39 (0.82 to 14.04) |
Fixed-effect or random-effect model, with application of the most conservative model in each case |
| Yates et al35 | 2020 | Tofacitinib, baricitinib, upadacitinib, filgotinib | RA, PsA, AS, UC, CD, CPP | 42 | RCT | 17 269 | Unavailable | 15 | 4 | All JAKis: 0.68 (0.36 to 1.29) | Mantel-Haenszel fixed-effect method |
| Wang et al36 | 2020 | Upadacitinib | RA | 3 | RCT | 2852 | Unavailable | 3 | 1 | 2.34 (0.15 to 15.02) | Random-effect model |
| Bilal et al37 | 2021 | Abrocitinib, baricitinib, decernotinib, filgotinib, peficitinib, ruxolitinib, tofacitinib | RA, AD, SLE, CPP, AS, PsA, UC, pancreatic cancer, breast cancer | 29 | RCT | 13 910 | 48 | 50 | 27 | All JAKis: 0.91 (0.57 to 1.47) Baricitinib: 1.12 (0.27 to 4.69) Decernotinib: 1.07 (0.18 to 6.43) Filgotinib: 2.13 (0.22 to 20.64) Ruxolitinib: (0.31 to 2.29) Upadacitinib: 2.25 (0.55 to 9.25) Tofacitinib: 0.27 (0.08 to 0.89) |
Random-effects model |
AD, atopic dermatitis; AS, ankylosing spondylarthritis; CD, Crohn’s disease; CPP, chronic plaque psoriasis; DKD, diabetic kidney disease; IR, incidence rate; JAKi, Janus kinase inhibitor; JIA, juvenile idiopathic arthritis; KT, kidney transplantation; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RCT, randomised clinical trial; SLE, systemic lupus erythematosus; SS, systemic sclerosis; UC, ulcerative colitis; VTE, venous thromboembolic event.